Abstract library

305 results for "Linhares Riello de Mello".
#2159 Hepatic Steatosis Secondary to Peptide Receptor Radionuclide Therapy with Somatostatin Analogue
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177-Lutetium-DOTA-TATE is a therapeutic modality for neuroendocrine tumors. It has some well known side effects, concerning specially the bone marrow (from cytopenias to myelodysplastic syndrome), in addition to mild renal effects. Hepatotoxicity from PRRT is still being studied.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: MD Beatriz Arruda Matheos de Lima
#725 Contrast-Enhanced Ultrasonography (CEUS) Predicts the Effectiveness of Anti-Angiogenic Therapies in Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Liver metastases (LM) from neuroendocrine tumors (NETs) exhibit a typical hypervascular pattern in the arterial phase on CEUS, allowing for a differential diagnosis between NET and non-NET LM. Medical therapy includes agents acting on angiogenesis and vascularization which may result in a change in CEUS findings.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Antonella Di Sarno
#2712 HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors (NET) and Hormone Receptor Positive Expression
Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Prof Rachel Riechelmann
#541 Contrast-Enhanced Ultrasound (CEUS) is a Helpful Tool to Predict the Effectiveness of Somatostatin Analogues in Patients with Liver Metastases From Neuroendocrine Tumors
Introduction: Contrast-enhanced ultrasonography (CEUS) allows characterization of the micro-vascularization of tumor lesions. Liver metastases (LM) from neuroendocrine tumors (NET) show a typical pattern on CEUS, consistent with a rapid, intense and homogeneous enhancement (hypervascular pattern) in the arterial phase.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Valeria Ramundo
#549 Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected with functioning well-differentiated neuroendocrine tumors (NET). There are no studies specifically focusing on NET associated to Multiple Endocrine Neoplasia type 1 (MEN-1).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Antongiulio Faggiano
#724 Contrast-Enhanced Ultrasonography (CEUS) Reliably Predicts Tumor Progression in Pancreatic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) exhibit a typical vascular pattern in the arterial phase on CEUS. The role of CEUS in the prognostic evaluation of pancreatic NET (pNET) has been poorly investigated.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Michela Del Prete
#751 Natural History of Resectable Large Cell Neuroendocrine Carcinoma of the Lung
Introduction: Lung large cell neuroendocrine carcinomas (LCNEC) are rare poorly differentiated carcinoma. Their natural history after surgery has been seldom studied.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Francesca Marciello
#901 Impact of Long-Acting Octreotide in Patients with Early-Stage MEN1-Related Duodeno-Pancreatic Neuroendocrine Tumors
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Valeria Ramundo
#904 Role of Metformin on Recurrence-Free Survival (RFS) in Neuroendocrine Tumors (NET)
Introduction: Recent data suggest metformin (Met) has antineoplastic properties in different type of cancer. Effects of Met have never been investigated in NET.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Francesca Marciello
#1187 High-Dose Treatment with Somatostatin Analogs in Neuroendocrine Tumors
Introduction: Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Roberta Modica